Ophthalmic Drugs Market By Type (Anti-Inflammatory Drugs, Anti-Infective Drugs, Anti-Glaucoma Drugs, Anti-Allergy Drugs, Anti-VEGF Agents, and Others), By Application (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, and Others), By Drug Delivery Types (Capsules & Tablets, Gels, Eye Drops, and Eye Ointment), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Ophthalmic drugs are used to treat an eye-related disorder, including dry eye, glaucoma, infection/inflammation, retinal disorders, and others. The ophthalmic drugs are available in the form of capsules & tablets, gels, eye drops, and eye ointment.

The Ophthalmic Drugs market was valued at 37.2 million US$ in 2022 and is projected to reach 64.4 million US$ by 2030, at a CAGR of 7.1% during the forecast period.

Market Dynamics

Increasing regulatory approval for ophthalmic drugs is boosting the global ophthalmic drugs market. For instance, the U.S. Food and Drug Administration (FDA) has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Tepezza was the first drug approved for the treatment of thyroid eye disease. Additionally, Novartis has received the U.S. Food and Drug Administration (FDA) approval for Beovu (brolucizumab) injection is also known as RTH258 for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to provide greater fluid resolution versus aflibercept and can maintain eligible wet age-related macular degeneration patients on a three-month dosing interval after a three-month loading phase. Further, the rising prevalence of eye-related disorders is a key driving factor of the market. However, product recall for ophthalmic drugs might hamper the market growth. For instance, Altaire Pharmaceuticals, Inc. has voluntarily recalled the Over the Counter (OTC) drug products and lots of Multiple Ophthalmic Products Sold At Wal-Mart. Altaire has recalled the product due to management concerns regarding Quality Assurance controls over critical systems in the manufacturing facility. The recall is carried out at the retail level. Moreover, increasing investment for ophthalmic drugs would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global ophthalmic drugs market is mainly classified based on type, application, and drug delivery types. Type is further segmented into Anti-Inflammatory Drugs, Anti-Infective Drugs, Anti-Glaucoma Drugs, Anti-Allergy Drugs, Anti-VEGF Agents, and Others. By application, the market is divided into Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, and Others. By drug delivery types, the market is further divided into Capsules & Tablets, Gels, Eye Drops, And Eye Ointment.

Anti-VEGF Agents was dominating the global ophthalmic drugs market in 2019, owing to the increasing commercialization of regulatory approved Anti-VEGF Agents, the collaboration between companies to develop Anti-VEGF Agents ophthalmic drugs, and increasing clinical studies on developing Anti-VEGF Agents ophthalmic drugs. For instance, PanOptica, Inc. is conducting a clinical study on PAN-90806, a topical formulation of a small-molecule anti-vascular endothelial growth factor eye drop for the treatment of neovascular eye diseases. In the clinical study PAN-90806, anti-VEGF eye drop demonstrated both safety and biological response.

Regional Analysis

Based on geography, the global ophthalmic drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global ophthalmic drugs market in 2019, due to the increasing commercialization of ophthalmic drugs, government support for the development of ophthalmic drugs, and rising prevalence of eye-related disorders. For instance, According to the Center for Chronic Disease Prevention, Glaucoma is a leading cause of irreversible blindness in the United States. In 2019, more than three million Americans are living with glaucoma, of which 2.7 million are aged 40 and older. Low vision and blindness affect 3.3 million Americans at the age of 40 and over. According to the Prevent Blindness America, Cataract is more common in women than in men. Cataract affects around 24.4 million Americans at the age of 40 and older. At the age of 80, more than half of the Americans have a cataract. Moreover, increasing regulatory approval for ophthalmic drugs is a key driving factor of the market. Alcon has received the Food and Drug Administration (FDA) approval to sale Pataday Once Daily Relief and Pataday Twice Daily Relief over the counter (OTC) in the U.S. Pataday is prescribed for eye allergy itch relief.

Competitive landscape

Key players operating in the ophthalmic drugs industry include Pfizer, Novartis, Bausch Health, Teva Pharmaceutical, Allergan, Mylan, Santen Pharmaceutical, Johnson & Johnson, APOTEX, Jamp Pharma, Senju Pharmaceutical, Sun Pharmaceutical, Horizon Therapeutics, Nicox S.A., and Aerie Pharmaceuticals, Inc.

The increasing regulatory approval of ophthalmic drugs, rising clinical studies on ophthalmic drugs, increasing research and development facilities for ophthalmic drugs, increasing investment for the development and commercialization of ophthalmic drugs, and commercialization of new ophthalmic drugs are some of the strategies adopted by the major companies. For instance, on October 14, 2019, Sun Pharmaceutical Industries Limited has introduced CEQUA for the treatment of dry eye disease in the US. CEQUA provide the highest concentration of cyclosporine for ophthalmic use. CEQUA is indicated to increase tear production in patients with Keratoconjunctivitis sicca in the U.S.

Ophthalmic Drugs Market Key Segments:

By Type
• Anti-Inflammatory Drugs
• Anti-Infective Drugs
• Anti-Glaucoma Drugs
• Anti-Allergy Drugs
• Anti-VEGF Agents
• Others

By Application
• Dry Eye
• Glaucoma
• Infection/Inflammation
• Retinal Disorders
• Others

By Drug Delivery Types
• Capsules & Tablets
• Gels
• Eye Drops
• Eye Ointment

Key Global Ophthalmic Drugs Industry Players
• Pfizer
• Novartis
• Bausch Health
• Teva Pharmaceutical
• Allergan
• Mylan
• Santen Pharmaceutical
• Johnson & Johnson
• APOTEX
• Jamp Pharma
• Senju Pharmaceutical
• Sun Pharmaceutical
• Horizon Therapeutics
• Nicox S.A.
• Aerie Pharmaceuticals, Inc.

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Ophthalmic Drugs Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing Regulatory Approval for Ophthalmic Drugs
3.3.2. Rising Prevalence of Eye-Related Disorders
3.4. Restraints
3.4.1. Product Recall for Ophthalmic Drugs
3.5. Opportunity
3.5.1. Increasing Investment for Ophthalmic Drugs
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Anti-Inflammatory Drugs
4.2.1. Market Size & Forecast
4.3. Anti-Infective Drugs
4.3.1. Market Size & Forecast
4.4. Anti-Glaucoma Drugs
4.4.1. Market Size & Forecast
4.5. Anti-Allergy Drugs
4.5.1. Market Size & Forecast
4.6. Anti-VEGF Agents
4.6.1. Market Size & Forecast
4.7. Others
4.7.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Dry Eye
5.2.1. Market Size & Forecast
5.3. Glaucoma
5.3.1. Market Size & Forecast
5.4. Infection/Inflammation
5.4.1. Market Size & Forecast
5.5. Retinal Disorders
5.5.1. Market Size & Forecast
5.6. Others
5.6.1. Market Size & Forecast

6. Drug Delivery Types Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. Capsules & Tablets
6.2.1. Market Size & Forecast
6.3. Gels
6.3.1. Market Size & Forecast
6.4. Eye Drops
6.4.1. Market Size & Forecast
6.5. Eye Ointment
6.5.1. Market Size & Forecast

7. Ophthalmic Drugs Market Regional Overview
7.1. Introduction
7.1.1. Market Size & Forecast
7.2. North America Ophthalmic Drugs Market
7.2.1. North America Market Size & Forecast, By Country
7.2.2. North America Market Size & Forecast, By Type
7.2.3. North America Market Size & Forecast, By Application
7.2.4. North America Market Size & Forecast, By Drug Delivery Types
7.2.5. U.S.
7.2.5.1. Market Size and Forecast
7.2.6. Canada
7.2.6.1. Market Size and Forecast
7.2.7. Mexico
7.2.7.1. Market Size and Forecast
7.3. Europe Ophthalmic Drugs Market
7.3.1. Europe Market Size & Forecast, By Country
7.3.2. Europe Market Size & Forecast, By Type
7.3.3. Europe Market Size & Forecast, By Application
7.3.4. Europe Market Size & Forecast, By Drug Delivery Types
7.3.5. Germany
7.3.5.1. Market Size and Forecast
7.3.6. France
7.3.6.1. Market Size and Forecast
7.3.7. UK
7.3.7.1. Market Size and Forecast
7.3.8. Italy
7.3.8.1. Market Size and Forecast
7.3.9. Spain
7.3.9.1. Market Size and Forecast
7.3.10. Rest of Europe
7.3.10.1. Market Size and Forecast
7.4. Asia-Pacific Ophthalmic Drugs Market
7.4.1. Asia-Pacific Market Size & Forecast, By Country
7.4.2. Asia-Pacific Market Size & Forecast, By Type
7.4.3. Asia-Pacific Market Size & Forecast, By Application
7.4.4. Asia-Pacific Market Size & Forecast, By Drug Delivery Types
7.4.5. Japan
7.4.5.1. Market Size and Forecast
7.4.6. China
7.4.6.1. Market Size and Forecast
7.4.7. Australia
7.4.7.1. Market Size and Forecast
7.4.8. India
7.4.8.1. Market Size and Forecast
7.4.9. South Korea
7.4.9.1. Market Size and Forecast
7.4.10. Rest of Asia-Pacific
7.4.10.1. Market Size and Forecast
7.5. South America Ophthalmic Drugs Market
7.5.1. South America Market Size & Forecast, By Country
7.5.2. South America Market Size & Forecast, By Type
7.5.3. South America Market Size & Forecast, By Application
7.5.4. South America Market Size & Forecast, By Drug Delivery Types
7.5.5. Brazil
7.5.5.1. Market Size and Forecast
7.5.6. Argentina
7.5.6.1. Market Size and Forecast
7.5.7. Rest of South America
7.5.7.1. Market Size and Forecast
7.6. Middle East & Africa Ophthalmic Drugs Market
7.6.1. Middle East & Africa Market Size & Forecast, By Country
7.6.2. Middle East & Africa Market Size & Forecast, By Type
7.6.3. Middle East & Africa Market Size & Forecast, By Application
7.6.4. Middle East & Africa Market Size & Forecast, By Drug Delivery Types
7.6.5. GCC Countries
7.6.5.1. Market Size and Forecast
7.6.6. Egypt
7.6.6.1. Market Size and Forecast
7.6.7. South Africa
7.6.7.1. Market Size and Forecast
7.6.8. Rest of Middle East & Africa
7.6.8.1. Market Size and Forecast

8. Company Profile
8.1. Pfizer
8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
8.1.2. Pfizer Product Category, Application, and Specification
8.1.3. Pfizer Financial Performance (2016-2018)
8.1.4. Main Business/Business Overview
8.2. Novartis
8.3. Bausch Health
8.4. Teva Pharmaceutical
8.5. Allergan
8.6. Mylan
8.7. Santen Pharmaceutical
8.8. Johnson & Johnson
8.9. APOTEX
8.10. Jamp Pharma
8.11. Senju Pharmaceutical
8.12. Sun Pharmaceutical
8.13. Horizon Therapeutics
8.14. Nicox S.A.
8.15. Aerie Pharmaceuticals, Inc.